[Actovegin treatment of duodenal ulcer associated with ischemic heart disease and diabetes mellitus].
Actovegin, a deproteinized hemoderivative, was used to correct bioenergetic defects of duodenal mucosa, to reduce inflammatory-cell infiltration, to stimulate blood supply of patients with duodenal ulcer associated with ischemic heart disease or diabetes mellitus. As shown by the results obtained in 194 patients (119 males and 75 females), adjuvant actovegin in patients with duodenal ulcer associated with ischemic heart disease and diabetes mellitus stimulates the ulcer healing, prolongs the recurrence-free interval. It can be used both in outpatient departments and specialized hospitals.
Smolianinov
A B
AB
D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001692:Biological Transport / Q000187:drug effects; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism; D004333:Drug Administration Routes; D004381:Duodenal Ulcer / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D004384:Duodenoscopy; D005260:Female; D005947:Glucose / Q000378:metabolism; D006418:Heme / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D055502:Secondary Prevention; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D006418:Heme; C015646:Actovegin; D000255:Adenosine Triphosphate; D005947:Glucose